Investor Presentaiton

Guardant360 has established footholds in the major tumor types for Therapy Selection GUARDANT 19% NSCLC 240K 21% 15% Breast CRC 119K Total Patients TAM is Stage IV patients, Data from internal modeling that sources information from US Cancer Statistics; SEER, Cancer MPact®, NODA data, Treatment Architecture, peer-reviewed literature, and Guardant Health data on file. 103K INVESTOR 20 DAY 23 77

View entire presentation